Distinguishing benign and malignant pelvic masses: The value of different diagnostic methods in everyday clinical practice

Engelen, M.J.A.; Bongaerts, Alphons H.H.; Sluiter, Wim J.; Haan, Harm H. de; Bogchelman, Dick H.; TenVergert, Elisabeth M.; Willemse, Pax H.B.; Zee, Ate G.J. van der

doi:10.1016/j.ejogrb.2006.10.004

Cited by 14 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to have patients treated by optional way, a correct preoperative diagnosis of pelvic masses is very important. Physical exam, imaging tests like computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, and ultrasound studies, and other tests may provide useful information about pelvic mass [17, 18]. However, it is very limited for one test to give an accurate diagnosis; for example, diagnostic ultrasound is only about 50% sensitive for stage I epithelial ovarian cancer and is further limited by poor specificity in accurately differentiating benign from malignant pathology [19].…”

Section: Discussionmentioning

confidence: 99%

Combined Application of Ultrasound and CT Increased Diagnostic Value in Female Patients with Pelvic Masses

Zhang

et al. 2016

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Purpose. The current study aimed to evaluate whether combined application of ultrasound and CT had increased Diagnostic Value in Female Patients with Pelvic Masses over either method alone. Patients and Methods. 240 female patients with pelvic masses were detected preoperatively with ultrasound and CT prior to surgery. The sensitivity, specificity, and accuracy of ultrasound, CT, and combined ultrasound/CT application were evaluated, respectively. Results. The sensitivity, specificity, and accuracy of ultrasound were 52.8%, 86.7%, and 68.75%, respectively. The sensitivity, specificity, and accuracy of CT were 80.3%, 90.3%, and 85%, respectively. The sensitivity, specificity, and accuracy of combined application of ultrasound and CT were 89%, 94.7%, and 91.7%. The sensitivity, specificity, and accuracy of combined application of ultrasound and CT were higher than those of either ultrasound or CT. Conclusions. The combined application of ultrasound and CT had higher Diagnostic Value in Female Patients with Pelvic Masses than either method alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined Application of Ultrasound and CT Increased Diagnostic Value in Female Patients with Pelvic Masses

Zhang

et al. 2016

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…However in this study, RMI 1 and 3 at the optimal cut off point of 265 and RMI2 at the optimal cut off point of 355, had a sensitivity of 91%, specificity of 96%, a positive predictive value of 78%, and a negative predictive value of 99%. Bailey et al study on 182 women with pelvic masses indicated an RMI > 200 had a sensitivity of 88.5% for diagnosing invasive lesions[12] while Engelen et al study on 302 women with pelvic mass indicated an RMI at a cut off point of 250 had a sensitivity of 88.2%, a specificity of 74.3%, a PPV of 71.3%, a NPV of 90% for diagnosing invasive lesions[13]. …”

Section: Discussionmentioning

confidence: 99%

Comparison of three malignancy risk indices and CA-125 in the preoperative evaluation of patients with pelvic masses

et al. 2011

View full text Add to dashboard Cite

BackgroundPatients with pelvic mass are the most referred patients to gynecologist. The aim of this study was to evaluate the ability of three malignancy risk indices (RMI 1, RMI 2 and RMI 3) and CA-125 to discriminate a benign from a malignant pelvic mass in our region (North of Iran).MethodsThis retrospective study was performed on 182 women with pelvic masses referred to Yahyanejad Hospital from 2007 to 2009. Ultrasound scans were scored as one point for each of the following characteristics: multilocular cyst, solid areas, intra-abdominal metastases, ascites, and bilateral lesions. For each patient a total ultrasound score (U) was calculated. The difference of the three RMI was based on the allocation of the U and M scores. The sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) of level of serum CA-125, the RMI 1, 2 and 3 were compared.ResultsMean age of the patients was 39.9 ± 9.3 years. Most of them were premenopausal (161 women or 88.4%). A significant linear trend for malignancy was found by increasing age, ultrasound score, and serum CA-125. The best performance of CA125 was at a cut-off 88 U/ml, with a sensitivity of 88%, a specificity of 97%, a positive predictive value of 84%, and a negative predictive value of 99%. RMI 1 and 3 at the optimal cut off point of 265 and RMI2 at the optimal cut off point of 355, had a sensitivity of 91%, specificity of 96%, a positive predictive value of 78%, and a negative predictive value of 99%.ConclusionIn our population we found that there is no statistically significant difference in the performance of three malignancy risk indices (RMI 1, RMI 2, and RMI 3) and CA125 in differentiating between benign and malignant pelvic masses.

show abstract

“…Explicit scoring systems such as risk of malignancy index (RMI), is based on the score obtained by ultrasound (U), menopausal status (M), and CA-125 data in the following manner: RMI=U×M×CA-125. A cutoff of 200 was used to differentiate between malignant and benign masses in the original study (13).Two studies reported on diagnostic accuracy of RMI (23,24). The overall sensitivity and specificity were 79.2% and 91.7%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Epidemiological data of ovarian cancer in Vojvodina and south great plain region in Hungary in 2007-2012 period: CrossBiomark IPA PROJECT HUSRB/1203/214/091

et al. 2013

View full text Add to dashboard Cite

Background: Ovarian cancer is among the sixth leading cancers in Vojvodina and the fifth leading cause of cancer death among female population in Vojvodina according to Cancer Registry of Vojvodina in 2010. The majority of ovarian cancers cases are diagnosed at an advanced stage, FIGO stage III-IV with poor prognosis. The aim of the study was to evaluate newly diagnosed ovarian cancer among female population in Vojvodina (Serbia) and South Great Plain region in Hungary in 2007- 2012 period. Methods: The evaluation was based on the data from hospital registries for malignant diseases at the Oncology Institute of Vojvodina and the Department of Oncotherapy, University of Szeged. Results: The majority of patients were diagnosed in advanced disease (FIGO stage III-IV) in both regions. Serous epithelial ovarian cancer was the most common cancer type among studied women in both regions. The average age of women diagnosed with ovarian cancer was 60 years; there was no significant statistical difference related to patients? age in both studied regions. Advanced stage of ovarian cancer investigated in our study showed a moderate descending liner trend with no significant statistical difference. The results from our study were similar when compared with the epidemiological data from the literature. Conclusion: The lack of efficient screening methods is the major obstacle to improve the prognosis of women affected by this disease. Further investigations and introduction of new technologies applied to medical discoveries offers new hope for finding effective screening policies.

show abstract

Distinguishing benign and malignant pelvic masses: The value of different diagnostic methods in everyday clinical practice

Cited by 14 publications

References 22 publications

Combined Application of Ultrasound and CT Increased Diagnostic Value in Female Patients with Pelvic Masses

Combined Application of Ultrasound and CT Increased Diagnostic Value in Female Patients with Pelvic Masses

Comparison of three malignancy risk indices and CA-125 in the preoperative evaluation of patients with pelvic masses

Epidemiological data of ovarian cancer in Vojvodina and south great plain region in Hungary in 2007-2012 period: CrossBiomark IPA PROJECT HUSRB/1203/214/091

Contact Info

Product

Resources

About